The MS International Federation (also known as MSIF) has compiled information and a video (available here) which sufficiently [...]
Satralizumab demonstrated robust efficacy, sustained for 144 weeks, in significantly reducing the risk of relapse in combination with [...]
CRANBURY, N.J.--(BUSINESS WIRE)--NeurologyLive™, a multimedia platform dedicated to providing health care professionals treating [...]
ROCKLAND, Mass., Sept. 10, 2019 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. [...]
Post-hoc analysis from a Phase III open-label extension study showed a 42% reduction in the risk of PPMS patients needing a wheelchair [...]
Pivotal Phase III SAkuraStar study shows 55% reduction in the risk of relapse for satralizumab monotherapy versus placebo presented at [...]
Blood neurofilament light chain (NfL) levels were significantly lowered following Ocrevus treatment in analyses of Phase III studies in RMS [...]
Investigational medicine satralizumab significantly reduces the risk of relapse in pivotal SAkuraStar monotherapy study for neuromyelitis [...]
Rutgers Health is leading the Pediatric Multiple Sclerosis and Demyelinating Diseases Program, the only program in the state of New [...]
Years ago, when many multiple sclerosis researchers believed that a type of immune cell known as a T-cell was the cause of the disease, Dr. [...]